Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response

od Guarducci, Cristina, Bonechi, Martina, Boccalini, Giulia, Benelli, Matteo, Risi, Emanuela, Di Leo, Angelo, Malorni, Luca, Migliaccio, Ilenia
Izdano u Breast Care (Basel) (2017)

HYDAMTIQ, a selective PARP‐1 inhibitor, improves bleomycin‐induced lung fibrosis by dampening the TGF‐β/SMAD signalling pathway

od Lucarini, Laura, Durante, Mariaconcetta, Lanzi, Cecilia, Pini, Alessandro, Boccalini, Giulia, Calosi, Laura, Moroni, Flavio, Masini, Emanuela, Mannaioni, Guido
Izdano u J Cell Mol Med (2016)

Protection from cigarette smoke‐induced vascular injury by recombinant human relaxin‐2 (serelaxin)

od Pini, Alessandro, Boccalini, Giulia, Baccari, Maria Caterina, Becatti, Matteo, Garella, Rachele, Fiorillo, Claudia, Calosi, Laura, Bani, Daniele, Nistri, Silvia
Izdano u J Cell Mol Med (2016)

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data

od Romagnoli, Dario, Boccalini, Giulia, Bonechi, Martina, Biagioni, Chiara, Fassan, Paola, Bertorelli, Roberto, Sanctis, Veronica De, Leo, Angelo Di, Migliaccio, Ilenia, Malorni, Luca, Benelli, Matteo
Izdano u BMC Genomics (2018)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy

od Bonechi, Martina, Galardi, Francesca, Biagioni, Chiara, De Luca, Francesca, Bergqvist, Mattias, Neumüller, Magnus, Guarducci, Cristina, Boccalini, Giulia, Gabellini, Stefano, Migliaccio, Ilenia, Di Leo, Angelo, Pestrin, Marta, Malorni, Luca
Izdano u Oncotarget (2018)

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

od Guarducci, Cristina, Bonechi, Martina, Benelli, Matteo, Biagioni, Chiara, Boccalini, Giulia, Romagnoli, Dario, Verardo, Roberto, Schiff, Rachel, Osborne, C. Kent, De Angelis, Carmine, Di Leo, Angelo, Malorni, Luca, Migliaccio, Ilenia
Izdano u NPJ Breast Cancer (2018)

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)

od Risi, Emanuela, Biagioni, Chiara, Benelli, Matteo, Migliaccio, Ilenia, McCartney, Amelia, Bonechi, Martina, Guarducci, Cristina, Hilbers, Florentine, Di Cosimo, Serena, Huober, Jens, Romagnoli, Dario, Boccalini, Giulia, Vitale, Stefania, Sotiriou, Christos, Biganzoli, Laura, Di Leo, Angelo, Malorni, Luca
Izdano u Ther Adv Med Oncol (2019)